Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Aikata H. Ando Y, et al. Among authors: okamoto w. Liver Cancer. 2022 Nov 29;12(3):251-261. doi: 10.1159/000528145. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37601981 Free PMC article.
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K. Kurata T, et al. Among authors: okamoto w. Invest New Drugs. 2014 Oct;32(5):946-54. doi: 10.1007/s10637-014-0112-7. Epub 2014 May 31. Invest New Drugs. 2014. PMID: 24875132 Clinical Trial.
[Current Status and Future Perspectives of SCRUM-Japan].
Ohtsu A, Goto K, Yoshino T, Okamoto W, Tsuchihara K. Ohtsu A, et al. Among authors: okamoto w. Gan To Kagaku Ryoho. 2017 Aug;44(8):621-626. Gan To Kagaku Ryoho. 2017. PMID: 28860428 Review. Japanese.
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A, Nakagawa K, Nagashima F, Shimizu T, Naruge D, Nishina S, Kitamura H, Kurata T, Takasu A, Fujisaka Y, Okamoto W, Nishimura Y, Mukaiyama A, Matsushita H, Furuse J. Kasuga A, et al. Among authors: okamoto w. Invest New Drugs. 2015 Oct;33(5):1058-67. doi: 10.1007/s10637-015-0270-2. Epub 2015 Aug 12. Invest New Drugs. 2015. PMID: 26259955 Clinical Trial.
Targeting MET Amplification as a New Oncogenic Driver.
Kawakami H, Okamoto I, Okamoto W, Tanizaki J, Nakagawa K, Nishio K. Kawakami H, et al. Among authors: okamoto w, okamoto i. Cancers (Basel). 2014 Jul 22;6(3):1540-52. doi: 10.3390/cancers6031540. Cancers (Basel). 2014. PMID: 25055117 Free PMC article.
108 results